Description:Severe asthmatic patients prescribed either Mepolizumab or Omalizumab were followed during treatment, and serum samples were collected before treatment (T0), and both at 6 (T1) and 18 months (T2) after starting biological treatment. Treatment monitoring was performed by the analysis of a set of inflammatory metabolites using targeted metabolomics.